NASDAQ:PRTA Prothena - PRTA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Prothena Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. $49.16 +1.04 (+2.16%) (As of 03/29/2023 03:21 PM ET) Add Compare Share Share Today's Range$48.44▼$49.5950-Day Range$46.97▼$58.2752-Week Range$21.06▼$66.47Volume286,452 shsAverage Volume495,946 shsMarket Capitalization$2.58 billionP/E RatioN/ADividend YieldN/APrice Target$82.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Prothena MarketRank™ ForecastAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside67.3% Upside$82.50 Price TargetShort InterestBearish6.56% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.17Based on 4 Articles This WeekInsider TradingSelling Shares$4.92 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.70) to ($4.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.98 out of 5 starsMedical Sector628th out of 999 stocksPharmaceutical Preparations Industry308th out of 489 stocks 3.4 Analyst's Opinion Consensus RatingProthena has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $82.50, Prothena has a forecasted upside of 67.3% from its current price of $49.30.Amount of Analyst CoverageProthena has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.56% of the outstanding shares of Prothena have been sold short.Short Interest Ratio / Days to CoverProthena has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Prothena has recently increased by 11.65%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldProthena does not currently pay a dividend.Dividend GrowthProthena does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRTA. Previous Next 2.3 News and Social Media Coverage News SentimentProthena has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Prothena this week, compared to 2 articles on an average week.Search Interest12 people have searched for PRTA on MarketBeat in the last 30 days. This is an increase of 9% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Prothena to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Prothena insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,920,937.00 in company stock.Percentage Held by Insiders31.20% of the stock of Prothena is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.72% of the stock of Prothena is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Prothena are expected to decrease in the coming year, from ($3.70) to ($4.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prothena is -19.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prothena is -19.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProthena has a P/B Ratio of 3.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Prothena (NASDAQ:PRTA) StockProthena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm's clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.Read More Receive PRTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter. Email Address PRTA Stock News HeadlinesMarch 23, 2023 | americanbankingnews.comProthena Co. plc (NASDAQ:PRTA) Receives Average Rating of "Moderate Buy" from BrokeragesMarch 20, 2023 | americanbankingnews.comProthena Co. plc (NASDAQ:PRTA) Insider Sells $726,600.00 in StockMarch 29, 2023 | Investor Place Media (Ad)The "King Of Quants" sees 10X potential...Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...March 16, 2023 | finance.yahoo.comProthena to Highlight Next Generation Treatments for Alzheimer’s and Parkinson’s Disease at the AD/PD 2023 MeetingMarch 10, 2023 | msn.comFmr Now Owns 10.02% of Prothena Corp (PRTA)March 1, 2023 | finance.yahoo.comAnalysts Just Made A Major Revision To Their Prothena Corporation plc (NASDAQ:PRTA) Revenue ForecastsFebruary 24, 2023 | finance.yahoo.comProthena (PRTA) Q4 Earnings and Revenues Beat EstimatesFebruary 1, 2023 | finance.yahoo.comProthena Touts Encouraging Data From Early-Stage Alzheimer's CandidateMarch 29, 2023 | Investor Place Media (Ad)The "King Of Quants" sees 10X potential...Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...January 15, 2023 | finance.yahoo.comProthena (NASDAQ:PRTA) shareholder returns have been strong, earning 299% in 3 yearsDecember 14, 2022 | msn.comWhy Prothena Shares Are Trading LowerDecember 14, 2022 | finance.yahoo.comProthena Announces Pricing of Public Offering of 3,250,000 Ordinary SharesDecember 13, 2022 | benzinga.comWhy Prothena Shares Are Nosediving During Tuesday's After-Hours SessionDecember 13, 2022 | finance.yahoo.comProthena Announces Proposed Public Offering of Ordinary SharesNovember 9, 2022 | finance.yahoo.comProthena Third Quarter 2022 Earnings: Misses ExpectationsNovember 7, 2022 | finance.yahoo.comCompanies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In GrowthOctober 27, 2022 | finance.yahoo.comProthena to Report Third Quarter 2022 Financial Results on November 3rdOctober 14, 2022 | reuters.comProthena Corporation PLCOctober 7, 2022 | nasdaq.comAnnovis (ANVS) Gains on FDA Authorization for AD Study - NasdaqOctober 6, 2022 | fool.comIs This Stock a Buy After Soaring by 37%? - The Motley FoolSeptember 30, 2022 | seekingalpha.comAcumen: ACU193 Is A Promising Phase 1 Alzheimer's Candidate, But Not More Than That - Seeking AlphaSeptember 29, 2022 | seekingalpha.comProthena: Paying A Premium To Cover All The Alzheimer's Bases (NASDAQ:PRTA) - Seeking AlphaSeptember 29, 2022 | benzinga.comNetflix, Biogen And Other Big Gainers From Wednesday - Alpha Metallurgical (NYSE:AMR), Acumen Pharmaceuti - BenzingaSeptember 29, 2022 | uk.investing.comNetflix, Biogen And Other Big Gainers From Wednesday By Benzinga - Investing.com UKSeptember 28, 2022 | benzinga.comUS Stocks Mixed; Wholesale Inventories Increase 1.3% In August - A2Z Smart Techs (NASDAQ:AZ), Acumen Phar - BenzingaSeptember 28, 2022 | morningstar.comDrug Companies Pursuing Alzheimer Treatments See Shares Rise Wednesday - MorningstarSeptember 28, 2022 | benzinga.comBenzinga's Top Ratings Upgrades, Downgrades For September 28, 2022 - Prothena Corp (NASDAQ:PRTA), BioRest - BenzingaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PRTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter. Email Address PRTA Company Calendar Last Earnings2/23/2023Today3/29/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRTA CUSIPN/A CIK1559053 Webwww.prothena.com Phone(531) 236-2500Fax353-1902-3510Employees82Year FoundedN/APrice Target and Rating Average Stock Price Forecast$82.50 High Stock Price Forecast$120.00 Low Stock Price Forecast$55.00 Forecasted Upside/Downside+67.3%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-116,950,000.00 Net Margins-216.95% Pretax Margin-233.01% Return on Equity-24.98% Return on Assets-19.15% Debt Debt-to-Equity RatioN/A Current Ratio14.34 Quick Ratio14.34 Sales & Book Value Annual Sales$53.90 million Price / Sales48.07 Cash FlowN/A Price / Cash FlowN/A Book Value$12.86 per share Price / Book3.83Miscellaneous Outstanding Shares52,560,000Free Float36,164,000Market Cap$2.59 billion OptionableOptionable Beta0.41 Key ExecutivesGene G. KinneyPresident, Chief Executive Officer & DirectorBrandon S. SmithChief Operating OfficerTran B. NguyenChief Financial & Strategy OfficerWagner M. ZagoChief Scientific OfficerHideki GarrenChief Medical OfficerKey CompetitorsGalapagosNASDAQ:GLPGSage TherapeuticsNASDAQ:SAGEHarmony BiosciencesNASDAQ:HRMYHUTCHMEDNASDAQ:HCMArrowhead PharmaceuticalsNASDAQ:ARWRView All CompetitorsInsiders & InstitutionsNeo Ivy Capital ManagementBought 15,120 shares on 3/27/2023Ownership: 0.029%Karin L. WalkerSold 5,000 sharesTotal: $238,600.00 ($47.72/share)Tran NguyenSold 10,000 sharesTotal: $484,300.00 ($48.43/share)Karin L. WalkerSold 20,000 sharesTotal: $968,400.00 ($48.42/share)Michael J. MalecekSold 15,000 sharesTotal: $726,600.00 ($48.44/share)View All Insider TransactionsView All Institutional Transactions PRTA Stock - Frequently Asked Questions Should I buy or sell Prothena stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRTA shares. View PRTA analyst ratings or view top-rated stocks. What is Prothena's stock price forecast for 2023? 8 brokerages have issued 1-year price targets for Prothena's shares. Their PRTA share price forecasts range from $55.00 to $120.00. On average, they anticipate the company's stock price to reach $82.50 in the next twelve months. This suggests a possible upside of 67.3% from the stock's current price. View analysts price targets for PRTA or view top-rated stocks among Wall Street analysts. How have PRTA shares performed in 2023? Prothena's stock was trading at $60.25 on January 1st, 2023. Since then, PRTA shares have decreased by 18.2% and is now trading at $49.30. View the best growth stocks for 2023 here. When is Prothena's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our PRTA earnings forecast. How were Prothena's earnings last quarter? Prothena Co. plc (NASDAQ:PRTA) announced its quarterly earnings results on Thursday, February, 23rd. The biotechnology company reported $0.12 earnings per share for the quarter, topping analysts' consensus estimates of ($0.64) by $0.76. The biotechnology company had revenue of $49.90 million for the quarter, compared to analysts' expectations of $29.14 million. Prothena had a negative net margin of 216.95% and a negative trailing twelve-month return on equity of 24.98%. The company's revenue was up 4058.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.71) earnings per share. What ETFs hold Prothena's stock? ETFs with the largest weight of Prothena (NASDAQ:PRTA) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC) and Invesco DWA SmallCap Momentum ETF (DWAS). What other stocks do shareholders of Prothena own? Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD). What is Prothena's stock symbol? Prothena trades on the NASDAQ under the ticker symbol "PRTA." Who are Prothena's major shareholders? Prothena's stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (6.63%), Avidity Partners Management LP (6.10%), First Light Asset Management LLC (3.17%), Dimensional Fund Advisors LP (2.73%), T. Rowe Price Investment Management Inc. (1.92%) and Geode Capital Management LLC (1.48%). Insiders that own company stock include Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Gene G Kinney, Hideki Garren, Karin L Walker, Karin L Walker, Lars Ekman, Michael J Malecek, Michael J Malecek, Richard T Collier, Shane Cooke, Tran Nguyen and Wagner M Zago. View institutional ownership trends. How do I buy shares of Prothena? Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Prothena's stock price today? One share of PRTA stock can currently be purchased for approximately $49.30. How much money does Prothena make? Prothena (NASDAQ:PRTA) has a market capitalization of $2.59 billion and generates $53.90 million in revenue each year. The biotechnology company earns $-116,950,000.00 in net income (profit) each year or ($2.51) on an earnings per share basis. How can I contact Prothena? Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The official website for the company is www.prothena.com. The biotechnology company can be reached via phone at (531) 236-2500, via email at ellen.rose@prothena.com, or via fax at 353-1902-3510. This page (NASDAQ:PRTA) was last updated on 3/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.